Company

Bank

Analyst

Coverage

Opinion

Wk chg

12/9 cls

Omeros Corp. (NASDAQ:OMER)

Rodman

Elemer Piros

Upgrade

Market outperform (from market perform)

3%

$4.04

Piros also set a $13 target ahead of what he anticipates will be positive data next quarter from a Phase III trial of Omeros' OMS302 to maintain pupil dilation during cataract and other lens replacement surgery and reduce postoperative pain and irritation. Piros also said he is "optimistic" about data anticipated in mid-2012 from a Phase III trial of OMS103HP to reduce pain and improve postoperative joint function following arthroscopic partial meniscectomy surgery. OMS302 is a combination of an undisclosed anti-inflammatory agent and a pupil dilation agent, and OMS103HP is a combination of ketoprofen, amitriptyline and oxymetazoline added to standard arthroscopic irrigation solutions.

Pharmacyclics Inc. (NASDAQ:PCYC)

Leerink

Jonathan Eckard

Price target

Market outperform

-21%

$12.39